Open Access

Molecular hydrogen improves type 2 diabetes through inhibiting oxidative stress

Retraction in: /10.3892/etm.2024.12591

  • Authors:
    • Yi Ming
    • Qi‑Hang Ma
    • Xin‑Li Han
    • Hong‑Yan Li
  • View Affiliations

  • Published online on: April 30, 2020     https://doi.org/10.3892/etm.2020.8708
  • Pages: 359-366
  • Copyright: © Ming et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the potential therapeutic effects of molecular hydrogen on type 2 diabetes mellitus (T2DM) in rats. Following maintenance on a high‑fat diet for 4 weeks, a T2DM model was established using an injection of 30 mg/kg streptozotocin via the caudal vein into Sprague‑Dawley rats. On day 0 and Day 80, the blood samples were obtained from each rat for the measurement of biochemical indicators including blood lipids, fasting blood glucose, hepatic glycogen, fasting serum insulin, insulin sensitivity index, insulin resistance index, serum superoxide dismutase (SOD) and serum malondialdehyde (MDA) using an automatic biochemical analyzer. The kidneys and pancreas tissues were harvested for HE staining and Western blot assay of toll‑like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), phosphorylated (p)‑p65, p65, p‑IκB and IκB. The results showed that in rats with T2DM, molecular hydrogen treatment decreased fasting blood glucose levels, increased hepatic glycogen synthesis and improved insulin sensitivity. Treatment with molecular hydrogen also increased the production of SOD whilst decreasing the production of MDA. In addition, molecular hydrogen alleviated the pathological changes exhibited by pancreatic islets and kidney during T2DM. Mechanistically, molecular hydrogen decreased TLR4 and MyD88 expression levels whilst also decreasing p65 and NF‑κB inhibitor phosphorylation. In conclusion, molecular hydrogen exerted therapeutic effects against T2DM by improving hyperglycemia and inhibiting oxidative stress through mechanisms that are associated with the TLR4/MyD88/NF‑κB signaling pathway.
View Figures
View References

Related Articles

Journal Cover

July-2020
Volume 20 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ming Y, Ma QH, Han XL and Li HY: Molecular hydrogen improves type 2 diabetes through inhibiting oxidative stress Retraction in /10.3892/etm.2024.12591. Exp Ther Med 20: 359-366, 2020.
APA
Ming, Y., Ma, Q., Han, X., & Li, H. (2020). Molecular hydrogen improves type 2 diabetes through inhibiting oxidative stress Retraction in /10.3892/etm.2024.12591. Experimental and Therapeutic Medicine, 20, 359-366. https://doi.org/10.3892/etm.2020.8708
MLA
Ming, Y., Ma, Q., Han, X., Li, H."Molecular hydrogen improves type 2 diabetes through inhibiting oxidative stress Retraction in /10.3892/etm.2024.12591". Experimental and Therapeutic Medicine 20.1 (2020): 359-366.
Chicago
Ming, Y., Ma, Q., Han, X., Li, H."Molecular hydrogen improves type 2 diabetes through inhibiting oxidative stress Retraction in /10.3892/etm.2024.12591". Experimental and Therapeutic Medicine 20, no. 1 (2020): 359-366. https://doi.org/10.3892/etm.2020.8708